For Immediate Release

AstraZeneca K.K.
Daiichi Sankyo Co., Ltd.

Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis

Tokyo, Japan, May 24 2011 - Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and AstraZeneca KK (an affiliate of AstraZeneca PLC; hereafter AstraZeneca) today announced a co-promotion agreement in Japan for Denosumab for the treatment of bone disorders stemming from bone metastasis.

 

Denosumab is the world’s first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Daiichi Sankyo acquired Denosumab right in 2007 from Amgen Inc., and filed a Japanese New Drug Application (JNDA) for it in August 2010.

 

 

NOTES TO EDITORS

 About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

 

Contacts:

AstraZeneca K.K.

Communications Department

Telephone: +81-6-6453-8011

http://www.astrazeneca.co.jp/

 

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

Telephone: +81-3-6225-1126

https://www.daiichisankyo.com